Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease.
Fiche publication
Date publication
juin 2015
Journal
Journal of pediatric gastroenterology and nutrition
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Fumery M, Jacob A, Sarter H, Michaud L, Spyckerelle C, Mouterde O, Savoye G, Colombel JF, Peyrin-Biroulet L, Gower-Rousseau C, Turck D,
Lien Pubmed
Résumé
The objective of the present study was to evaluate the effectiveness and safety of adalimumab (ADA) in children with Crohn disease (CD) who experienced infliximab (IFX) failure at the population level.
Mots clés
Adalimumab, administration & dosage, Adolescent, Antibodies, Monoclonal, administration & dosage, C-Reactive Protein, analysis, Child, Child Development, drug effects, Crohn Disease, blood, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infliximab, administration & dosage, Male, Nutritional Status, drug effects, Orosomucoid, analysis, Remission Induction, methods, Retrospective Studies, Time Factors, Treatment Failure, Treatment Outcome
Référence
J. Pediatr. Gastroenterol. Nutr.. 2015 Jun;60(6):744-8